GuruFocus · OS · October 25, 2026

Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01

Get the app for more

Explore stock news, insights and company research.